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REPLY
Dr. McLellan points out that exercise has been shown to make
subjects respond to subsequent exercise like caffeine-naïve subjects.
We welcome this information, which seems to further strengthen
our results (1), as it confirms that the sensitivity to caffeine is more
pronounced during exercise.
However, based on our power calculation we cannot support the
statement that increasing the study population and splitting it up
into placebo and caffeine groups would have improved the quality
of the study; as with the crossover design, each subject served as its
own control, an advantage that would have been lost following the
advice of Dr. McLellan.
Although some positive effects of caffeine on exercise perfor-
mance might have been reported in studies more than 2 decades
ago (as cited by Dr. McLellan), this seems to be challeneged by
more recent experiences, which have led to removing caffeine from
the doping list (2). We remain reluctant to comment on this,
because this parameter was beyond the scope of our study, which
was designed to assess the effect of caffeine on exercise-induced
myocardial perfusion response.
Furthermore, it has been brought to our attention that the
values for mean arterial pressure (MAP) in Table 1 of our report
were regrettably incorrect. The correct values are given in the
revised table (Table 1).
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Management of Women
With Acute Coronary Syndromes
In a recent study published in the Journal, Anand et al. (1) show
that women with acute coronary syndromes underwent less
coronary angiography and revascularization and had a higher
rate of refractory ischemia and rehospitalization than their male
counterparts. It is important to understand that these state-
ments are true—true, but not necessarily related. The difference
in total revascularization rates in high-risk female and male
populations was only 2.5%; this rate difference could not negate
the 8.6% difference in refractory ischemia/revascularization
rates between genders. Indeed, there is no direct evidence that
increasing the revascularization rate would change outcomes in
these women. As Anand et al. (1) point out, there is a relative
paucity of information regarding the appropriate treatment of
coronary artery disease in women. Moreover, their data dem-
onstrate the conundrum physicians face—namely, that women
have a lower prevalence of disease but are harder to treat
successfully.
Treatment mores demand that a treatment be of proven efficacy
and acceptable harm. If a physician hesitates in applying treatment
recommendations that are proven for men but not for women, to
a female patient, is that gender bias or good evidence-based
Table 1. Hemodynamics
Normoxia Hypoxia
Baseline Caffeine p Baseline Caffeine p
Rest
SBP (mm Hg) 124  12 120  11 NS 129  12 125  16 NS
DBP (mm Hg) 73  10 71  11 NS 69  8 70  11 NS
MAP (mm Hg) 90  9 87  8 NS 89  8 88  11 NS
HR (beats/min) 66  13 65  11 NS 77  11 78  21 NS
RPP (mm Hg  beats/min) 8,179  1,933 7,771  1,037 NS 9,996  2,265 9,860  3,362 NS
Peak exercise
SBP (mm Hg) 152  21 159  19 NS 152  11 154  10 NS
DBP (mm Hg) 90  9 95  4 NS 88  5 92  6 NS
MAP (mm Hg) 111  13 116  9 NS 110  6 112  7 NS
HR (beats/min) 153  4 154  8 NS 168  9 164  8 NS
RPP (mm Hg  beats/min) 23,173  3,487 24,382  2,360 NS 25,591  1,774 25,274  2,287 NS
Corrected values indicated in bold.
DBP  diastolic blood pressure; HR  heart rate; MAP  mean arterial blood pressure; RPP  rate pressure product; SBP  systolic blood pressure.
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